• Aclacinomycin A and rDNA Stress: What Evidence Shows

  2026-10-05

  A source-grounded overview of Aclacinomycin A, or Aclarubicin, in relation to ribosomal-DNA damage, PML-nucleolar associations, apoptosis, and topoisomerase stress. The central limitation is that the cited rDNA study examined doxorubicin rather than Aclacinomycin A, so mechanistic equivalence cannot be assumed.

• Human SAN-Plexus Assembloids and Pacemaker Maturation

  2026-10-05

  Zhang and colleagues developed human pluripotent stem cell-derived assembloids that combine sinoatrial node, cardiac plexus, and atrial-like organoids to model neural control of pacemaker activity. Their integrated functional and spatial-transcriptomic analyses support a prosaposin–GPR37 signaling program associated with sinoatrial node maturation, while also defining important boundaries for interpreting this in vitro system.

• ABCC10, cGAMP Efflux, and Radiotherapy Resistance

  2026-10-04

  A 2025 Cell Death & Differentiation study identifies ABCC10 as a cGAMP exporter that weakens STING-TBK1-IRF3 signaling and contributes to cancer-cell radiotherapy resistance. The findings connect nucleotide transport with DNA-damage responses and suggest that ABCC10 may be relevant as a biomarker or therapeutic research target, although clinical transferability remains unestablished.

• BML-277 and CHK2: Evidence, Scope and Limits

  2026-10-03

  A source-grounded overview of BML-277 and CHK2 biology, separating supplier-reported inhibitor claims from findings in a primary study of the nuclear cGAS–CHK2–TRIM41 pathway. It examines evidence quality, interpretation, applicability to DNA damage response research, and key limitations.

• MDM1, p53, and Chemoradiotherapy Sensitivity in CRC

  2026-10-02

  The reference study identifies MDM1 as both a marker and mechanistic regulator of chemoradiotherapy response in colorectal cancer, linking MDM1 overexpression to reduced YBX1 occupancy at the TP53 promoter, increased p53 expression, and apoptosis. Its genetic, transcriptomic, molecular, and xenograft experiments provide a framework for biomarker-guided investigation of treatment resistance, while requiring further clinical validation.

• Phalloidin B7678: Fixed-Cell F-Actin Workflow

  2026-10-01

  Phalloidin (B7678) is a cyclic heptapeptide toxin that binds filamentous actin with high affinity for fixed-cell, permeabilized-sample, tissue-section, and cell-free cytoskeleton visualization. It is not appropriate for live-cell imaging or experiments that require reversible actin turnover because filament stabilization can perturb cytoskeletal dynamics and cell locomotion.

• Thermal-Protective Hydrogel for Tumor Ablation

  2026-10-01

  The reference study presents MR@CaP@HA, an injectable hydrogel that combines local thermal insulation with pH- and glutathione-responsive delivery of mitoxantrone and Resiquimod (R-848) during radiofrequency ablation. In preclinical models, this integrated design protected adjacent tissue, promoted immunogenic cell death and immune-cell reprogramming, and produced complete tumor eradication in a subset of treated animals.

• Protease Inhibitor Cocktail EDTA-Free: K1007 Guide

  2026-09-30

  Protease Inhibitor Cocktail EDTA-Free K1007 is a 100X DMSO formulation for limiting proteolysis during cell and tissue lysis. Its EDTA-free design supports workflows that require divalent cations, including phosphorylation analysis and enzyme assays, while the cited MRSA study provides infection-model context rather than direct product validation.

• Cucurbitacin I (JSI-124): STAT3 Research Guide

  2026-09-30

  Cucurbitacin I, also called JSI-124, is a research compound used to perturb JAK2/STAT3 signaling in cancer models. Evidence supports pathway-level inhibition through reduced STAT3 phosphorylation, DNA binding, and downstream transcription, while product data also report apoptosis, migration inhibition, and tumor growth inhibition in vivo.

• GSK 2837808A: Mapping the LDHA–Lactate Axis

  2026-09-29

  GSK 2837808A offers a selective way to test how LDHA-dependent lactate production connects glycolytic flux with immune regulation. This thought-leadership article links validated hepatocellular carcinoma findings with the NAT1–ENO1–lactate–PD-L1 mechanism reported in colorectal cancer, while defining the exposure, biomarker, and experimental controls needed before translational claims can be made.

• 2'3'-cGAMP (Sodium Salt) for STING Research

  2026-09-29

  2'3'-cGAMP (sodium salt) is an endogenous cGAS-derived STING agonist that activates TBK1–IRF3 signaling and type I interferon induction. Its defined composition, reported 3.79 nM STING-binding affinity, and use in cancer-immunology studies make it a practical reagent for dissecting the cGAS-STING signaling pathway.

• Nuclear cGAS, Chk2, and L1 Genome Defense

  2026-09-28

  This study identifies a posttranslational mechanism in which nuclear cGAS suppresses LINE-1 retrotransposition by promoting TRIM41-dependent ubiquitination and degradation of ORF2p. It further places CHK2 upstream of this pathway during DNA damage, providing a mechanistic link between genome surveillance, retrotransposon control, aging, and tumorigenesis.

• Direct Mouse Genotyping Kit Plus: Evidence & Workflow

  2026-09-28

  The Direct Mouse Genotyping Kit Plus combines mouse-tissue lysis with direct PCR and a PCR master mix with dye reagents. This purification-free workflow can simplify routine mouse genotyping, while genotype-specific assay design and validation remain the researcher’s responsibility.

• Chlorpromazine Workflows for CNS and Cell Assays

  2026-09-27

  Use Chlorpromazine as a receptor-pharmacology probe for dopamine D2 signaling and antiemetic research, with controls designed to separate target-related effects from broader cellular responses. A liver nanoparticle study offers a useful lesson in cell-resolved assay design—not evidence that chlorpromazine changes nanoparticle uptake.

• Fluconazole Workflows for Candida Biofilm Research

  2026-09-26

  Use Fluconazole to connect ergosterol-pathway inhibition with susceptibility, biofilm, and resistance experiments—not just planktonic growth curves. A practical workflow pairs dose-response testing with PP2A–autophagy comparisons, while controlling for solvent, strain, and biofilm-specific assay effects.

8025 records 1/535 page Next 12345 下5页 Last page